Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Thol

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
Pageof 13